Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity
Open Access
- 16 January 2004
- journal article
- research article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 11 (3) , 174-185
- https://doi.org/10.1038/sj.cgt.7700666
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Dendritic cells reconstituted with human telomerase gene induce potent cytotoxic T-cell response against different types of tumorsCancer Gene Therapy, 2003
- Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agentsCancer Cell, 2002
- hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicityGene Therapy, 2002
- Oncolytic viruses as therapeutic agentsAnnals of Medicine, 2001
- Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigenJournal of Clinical Investigation, 2000
- Efficacy of herpes simplex virus thymidine kinase in combination with cytokine gene therapy in an experimental metastatic breast cancer modelCancer Gene Therapy, 2000
- Telomerase Catalytic Subunit Homologs from Fission Yeast and HumanScience, 1997
- A survey of telomerase activity in human cancerPublished by Elsevier ,1997
- Specific Association of Human Telomerase Activity with Immortal Cells and CancerScience, 1994
- Telomeres shorten during ageing of human fibroblastsNature, 1990